ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1050

Pharmacokinetic and pharmacodynamic modelling of the novel anti-ADAMTS-5 nanobody M6495 using the neo-epitope ARGS as a biomarker

Joao Pereira1, Ingrid Ottevaere2, Benedikte Serruys2, Eline Dejonckheere2, Anne C. Bay-Jensen3, Anne Sofie Siebuhr4, Samer El Bawab1, Christoph Ladel1 and Sven Lindemann1, 1Merck KGaA, Darmstadt, Germany, 2Ablynx NV, Zwijnaarde, Belgium, 3Nordic Bioscience, Herlev, Denmark, 4Biomarkers and Research, Nordic Bioscience, Herlev, Denmark

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Osteoarthritis and pharmacokinetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The anti-ADAMTS-5 Nanobody®, M6495, is a first-in-class, highly selective, bifunctional Nanobody® and a potent inhibitor of ADAMTS-5, with the potential to be the first self-administered disease modifying osteoarthritis drug (DMOAD). A model-based approach was used to explore the relationship between plasma concentrations of M6495 and the reduction of serum concentrations of the target engagement biomarker, the ADAMTS-5 generated neo-epitope of aggrecan (ARGS), in cynomolgus monkeys.

Methods: A dedicated single dose pharmacokinetics and pharmacodynamics (PK/PD) study was conducted in cynomolgus monkeys receiving subcutaneous (SC) M6495 at doses ranging from 0.01 to 6 mg/kg or vehicle. An additional group received intravenous M6495 which allowed the estimation of bioavailability. Both M6495 and ARGS concentrations were measured over time. The data were then pooled with PK/PD data collected in a separate multiple-dose study in cynomolgus monkeys that received weekly M6495 at doses up to 150 mg/kg. Plasma concentrations of M6495 and decrease in ARGS serum concentrations upon drug administration were modelled with a non-linear mixed effects PK/PD model.

Results: A 2-compartment model including linear and non-linear elimination from the central compartment and first order absorption upon SC administration, adequately described the drug concentration-time profiles of M6495. The non-linear PK indicated a mechanism of target-mediated drug disposition which can be saturated at higher serum concentrations of M6495. ARGS levels decreased upon drug administration, with higher decrease demonstrable at higher doses (see Figure), reaching levels below the lower limit of quantification (LLOQ) for M6495 doses of 6 mg/kg and higher, indicating a strong inhibition of ADAMTS-5 (higher than 70%). Furthermore, the bioavailability after SC injection was estimated to be close to 100%. A marked decrease in serum ARGS levels, lasting several weeks, could already be observed after a single dose of M6495. The decrease in ARGS serum concentrations was delayed in relation to the exposure, and could be described with an indirect response model.

Conclusion: A single injection of the anti-ADAMTS-5 Nanobody®, M6495, in cynomolgus monkeys lead to a long-lasting decrease in ARGS at the highest dose tested, indicating a long-term inhibition of ADAMTS-5. This PK/PD model can be used to explore the exposure/pharmacodynamic response relationship between M6495 serum concentrations and the ARGS serum biomarker.

 

 


Disclosure: J. Pereira, Merck KGaA, 3; I. Ottevaere, Ablynx NV, Belgium, 3; B. Serruys, Ablynx, 3; E. Dejonckheere, Ablynx NV, Belgium, 3; A. C. Bay-Jensen, Nordic Bioscience, 1, 3,IMI APPROACH, 2; A. S. Siebuhr, Nordic Bioscience, 3; S. El Bawab, Merck KGaA, 3; C. Ladel, Merck KGaA, 3; S. Lindemann, Merck KGaA, 3.

To cite this abstract in AMA style:

Pereira J, Ottevaere I, Serruys B, Dejonckheere E, Bay-Jensen AC, Siebuhr AS, El Bawab S, Ladel C, Lindemann S. Pharmacokinetic and pharmacodynamic modelling of the novel anti-ADAMTS-5 nanobody M6495 using the neo-epitope ARGS as a biomarker [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/pharmacokinetic-and-pharmacodynamic-modelling-of-the-novel-anti-adamts-5-nanobody-m6495-using-the-neo-epitope-args-as-a-biomarker/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacokinetic-and-pharmacodynamic-modelling-of-the-novel-anti-adamts-5-nanobody-m6495-using-the-neo-epitope-args-as-a-biomarker/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology